Maravai LifeSciences Holdings Inc. Class A Common Stock vs Newmont Corporation — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Newmont Corporation trades at $111.91 (market cap $121.80B). The key difference: Newmont Corporation is far larger — about 125.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Newmont Corporation pays a 0.9% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Newmont Corporation for 59 Days on average.
| MRVI | NEM | |
|---|---|---|
Market Cap | $972.90M | $121.80B |
Volume | 4,325,710 | 4,383,120 |
Sector | Health | Basic Materials |
52-Week High | $9.00 | $135.14 |
52-Week Low | $2.83 | $78.63 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $1.08B | $118.39B |
Dividend Yield | — | 0.9% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Newmont Corporation (NEM) trades at $111.56, down 4.77% over the past 24 hours, with strong fundamental performance including record free cash flow of $5.3 billion in H1 2026 and three consecutive quarterly earnings beats. The stock shows a bullish technical signal with moving averages supporting upward momentum, while maintaining attractive valuation metrics including a P/E of 14.58 and EV/EBITDA of 7.38. Recent news highlights the company's focus on per-share growth and operational improvements amid constructive gold market conditions.
Newmont presents a compelling investment case with robust profitability (33.36% net margin), strong analyst consensus (76% buy ratings), and 22% upside to the $136.83 price target. Key risks include gold price volatility and execution of growth initiatives, but the company's record cash flow generation and improving balance sheet provide solid foundation for continued shareholder value creation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →